睿知中国疾病研究地图
候选清单0

南通南通大学

南通大学附属医院

Affiliated Hospital of Nantong University

在本站收录的 53 种疾病中,这家医院列在其中 21 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

南通大学附属医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma20 篇牵头论文牵头 1 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma22 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma145 篇牵头论文
  4. 胃癌Stomach cancer107 篇牵头论文牵头 1 项开放试验
  5. 骨肉瘤Osteosarcoma9 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour3 篇牵头论文
  7. 神经母细胞瘤Neuroblastoma10 篇牵头论文
  8. 多发性骨髓瘤Multiple myeloma16 篇牵头论文牵头 1 项开放试验
  9. 再生障碍性贫血Aplastic anaemia2 篇牵头论文
  10. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis3 篇牵头论文
  11. 血友病 AHaemophilia A0 篇牵头论文
  12. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome1 篇牵头论文
  13. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  14. 特发性肺纤维化Idiopathic pulmonary fibrosis4 篇牵头论文
  15. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis5 篇牵头论文
  16. 杜氏肌营养不良Duchenne muscular dystrophy2 篇牵头论文
  17. IgA 肾病IgA nephropathy1 篇牵头论文
  18. 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
  19. 先天性巨结肠Hirschsprung disease0 篇牵头论文
  20. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa1 篇牵头论文
  21. Leber 遗传性视神经病变Leber hereditary optic neuropathy1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、脊索瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、β 地中海贫血、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、遗传性血管性水肿、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 20 篇,占 0.8%。

牵头论文
20
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 3320222023: 3320232024: 3320242025: 552025

南通有 1 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
    分期
    不分期
    开始
    2024-08
    登记号
    NCT06389201

    年龄 20 岁 至 70 岁(登记的条件)

    牵头:南通大学附属医院南通

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与转移诱导/同步化疗
论文中的科室耳鼻喉/头颈外科

这些论文过半是实验室或动物研究。

牵头的论文20
  1. RFC5 enhances DNA damage response and immune escape via suppressing the cGAS-STING pathway in nasopharyngeal carcinoma.2026Cellular signalling
  2. DDX5 super-enhancer promotes vasculogenic mimicry formation and metastasis in nasopharyngeal carcinoma by enhancing ADAM10 transcription.2025Cell reports. Medicine免费全文
  3. IGF2BP1-HAX-1 positive feedback loop-mediated HAX-1 overexpression blocks autophagic flux and promotes chemoresistance in nasopharyngeal carcinoma.2025Cellular and molecular life sciences : CMLS免费全文
  4. LPAR3 and COL8A1, as matrix stiffness-related biomarkers, promote nasopharyngeal carcinoma metastasis by triggering EMT and angiogenesis.2025Cellular signalling
  5. Hot spots and trends related to chemotherapy in nasopharyngeal carcinoma [2014-2024]: a bibliometric study.2025Chinese clinical oncology
  6. Acetyltransferase NAT10 inhibits T-cell immunity and promotes nasopharyngeal carcinoma progression through DDX5/HMGB1 axis.2025Journal for immunotherapy of cancer免费全文
  7. NAT10 inhibition promotes ac4C-dependent ferroptosis to counteract sorafenib resistance in nasopharyngeal carcinoma.2024Cancer science免费全文
  8. Stiffness promotes cell migration, invasion, and invadopodia in nasopharyngeal carcinoma by regulating the WT-CTTN level.2024Cancer science
  9. FGF19 promotes nasopharyngeal carcinoma progression by inducing angiogenesis via inhibiting TRIM21-mediated ANXA2 ubiquitination.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  10. RCN2 promotes Nasopharyngeal carcinoma progression by curbing Calcium flow and Mitochondrial apoptosis.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  11. Effects of abnormal expression of CD73 on malignant phenotype of nasopharyngeal carcinoma.2023Journal of molecular histology
  12. Hypoxic nasopharyngeal carcinoma-derived exosomal miR-455 increases vascular permeability by targeting ZO-1 to promote metastasis.2023Molecular carcinogenesis
  13. AMPK-mTOR-Mediated Activation of Autophagy Promotes Formation of Dormant Polyploid Giant Cancer Cells.2022Cancer research免费全文
  14. Extracellular vesicles rich in HAX1 promote angiogenesis by modulating ITGB6 translation.2022Journal of extracellular vesicles免费全文
  15. Tumor-derived exosomal lincRNA ROR promotes angiogenesis in nasopharyngeal carcinoma.2022Molecular and cellular probes
  16. MIR106A-5p upregulation suppresses autophagy and accelerates malignant phenotype in nasopharyngeal carcinoma.2021Autophagy免费全文
  17. Exosomal ERp44 derived from ER-stressed cells strengthens cisplatin resistance of nasopharyngeal carcinoma.2021BMC cancer免费全文
  18. HIF-1α downregulation of miR-433-3p in adipocyte-derived exosomes contributes to NPC progression via targeting SCD1.2021Cancer science免费全文
  19. Nuclear exosome HMGB3 secreted by nasopharyngeal carcinoma cells promotes tumour metastasis by inducing angiogenesis.2021Cell death & disease免费全文
  20. ER resident protein 44 promotes malignant phenotype in nasopharyngeal carcinoma through the interaction with ATP citrate lyase.2021Journal of translational medicine免费全文
中文论文(未计入)2
  1. [An analysis of long-term survival trends for nasopharyngeal carcinoma in Qidong, Jiangsu].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [Autophagy promotes recurrence of nasopharyngeal carcinoma via inducing the formation of dormant polyploid giant cancer cells].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients正在招募NCT06389201牵头方不分期2024-08 启动
  2. Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients状态不明NCT06442709牵头方不分期2021-08 启动
  3. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)已完成NCT03924986研究中心III期2019-03 启动
PubMed 以外找到的论文(未计入)4
  1. WITHDRAWN: 1440TiP Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine(GX) versus tislelizumab plus gemcitabine/cisplatin(GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multic2025Annals of Oncology撤稿
  2. Data from AMPK–mTOR–Mediated Activation of Autophagy Promotes Formation of Dormant Polyploid Giant Cancer Cells2023未列出期刊其他
  3. MicroRNA-433 Inhibits Migration and Proliferation of Nasopharyngeal Carcinoma by Targeting Hypoxia- Induced Factor 1α2022Research Square预印本
  4. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 22 篇,占 0.8%。

牵头论文
22
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 7720222023: 3320232024: 4420242025: 662025

南通有 2 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    分期
    未注明
    开始
    2022-07
    登记号
    NCT05443841

    年龄未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院;另有 8 家列出的医院为研究中心上海、南通、合肥、天津、泰州、石家庄、西安、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题分子标志物与基因影像与人工智能免疫治疗
论文中的科室影像/核医学科肿瘤内科病理/检验科放疗科
牵头的论文22
  1. Preoperative esophageal cancer staging assessment based on intravoxel incoherent motion and apparent diffusion coefficient: a comparative study of maximum-diameter slice region of interest and whole volume of interest analysis.2025BMC medical imaging免费全文
  2. CAFs-derived Exosomal miR-889-3p Might Repress M1 Macrophage Polarization to Boost ESCC Development by Regulating STAT1.2025Cell biochemistry and biophysics
  3. SUMO-Specific Peptidase 5 Promotes Oesophageal Squamous Cell Carcinoma Growth through the NF-κB-SLC1A3 Axis.2025Frontiers in bioscience (Landmark edition)
  4. Multi-cohort validation based on coagulation-related genes for predicting prognosis of esophageal squamous cell carcinoma.2025Frontiers in immunology免费全文
  5. Correlation of immune cell subsets in the tumor microenvironment and peripheral blood with immunotherapy response in esophageal squamous cell carcinoma.2025Frontiers in immunology免费全文
  6. TAK1-mediated phosphorylation of PLCE1 represses PIP2 hydrolysis to impede esophageal squamous cancer metastasis.2025eLife免费全文
  7. Preoperative Prediction of Perineural Invasion in Oesophageal Squamous Cell Carcinoma Based on CT Radiomics Nomogram: A Multicenter Study.2024Academic radiology
  8. Clinicopathological, metastatic and prognostic features of stage IV esophageal adenocarcinoma versus squamous cell carcinoma: a SEER database analysis.2024Chinese clinical oncology
  9. TAPI-1 Exhibits Anti-tumor Efficacy in Human Esophageal Squamous Cell Carcinoma Cells via Suppression of NF-κB Signaling Pathway.2024Digestive diseases and sciences免费全文
  10. SPINK5 inhibits esophageal squamous cell carcinoma metastasis via immune activity.2024The journal of gene medicine
  11. Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.2023Cancer medicineRCT免费全文
  12. High Expression Level of BRD4 Is Associated with a Poor Prognosis and Immune Infiltration in Esophageal Squamous Cell Carcinoma.2023Digestive diseases and sciences免费全文
  13. AKAP12 inhibits esophageal squamous carcinoma cell proliferation, migration, and cell cycle via the PI3K/AKT signaling pathway.2023Molecular and cellular probes
  14. Computed Tomography-Based Radiomics Nomogram for Predicting the Postoperative Prognosis of Esophageal Squamous Cell Carcinoma: A Multicenter Study.2022Academic radiologyRCT
  15. Low expression of PRDM5 predicts poor prognosis of esophageal squamous cell carcinoma.2022BMC cancer免费全文
  16. HLA complex P5 upregulation is correlated with poor prognosis and tumor progression in esophageal squamous cell carcinoma.2022Bioengineered免费全文
  17. New Metabolic Alterations and A Predictive Marker Pipecolic Acid in Sera for Esophageal Squamous Cell Carcinoma.2022Genomics, proteomics & bioinformatics免费全文
  18. RASSF10 exhibits tumor‑suppressing potential involving tumor proliferation, metastasis and epithelial‑mesenchymal transition in esophageal squamous cell carcinoma.2022Oncology reports免费全文
  19. Computed tomography-based radiomics analysis to predict lymphovascular invasion in esophageal squamous cell carcinoma.2022The British journal of radiology免费全文
  20. Effect of different surgical approaches on the prognosis of patients with postoperative radiotherapy for stage IIB-IVA esophageal squamous cancer.2022World journal of surgical oncology免费全文
  21. Esophageal Carcinosarcoma: Analysis of Clinical Features and Prognosis of 24 Cases and a Literature Review.2021Cancer control : journal of the Moffitt Cancer Center免费全文
  22. Pyk2 level is a novel prognostic marker for patients with esophageal squamous cell carcinoma after radical surgery.2021Virchows Archiv : an international journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC状态不明NCT06186609牵头方II期2023-07 启动
  2. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)正在招募NCT05443841研究中心2022-07 启动
PubMed 以外找到的论文(未计入)3
  1. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  2. MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel2021Figshare数据集
  3. Radical Resection of T3N2M0 Esophageal Cancer Under Bilateral Thoracoscopy: A Case Report2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 145 篇,占 1.0%。

牵头论文
145
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 151520212022: 181820222023: 313120232024: 454520242025: 32322025

南通有 2 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现免疫与靶向药物
论文中的科室普外/肝胆胰外科病理/检验科影像/核医学科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文145
  1. PD-1+/CXCR6+CD8+T lymphocytes promote MASLD malignant progression through inflammatory and immune dysregulation.2026International immunopharmacology
  2. Prediction of PD-1 Expression and Outcomes of Combined Therapy in Hepatocellular Carcinoma: an MRI-Based Radiomics Approach.2026Journal of imaging informatics in medicine免费全文
  3. Outcomes of laparoscopic versus open liver resection in patients with large or huge HCC: a multicenter study.2026Surgical endoscopy
  4. A multicenter case-controlled study on laparoscopic hepatectomy versus open liver resection as first-line therapy for solitary hepatocellular carcinoma in elderly patients.2026Surgical endoscopy
  5. tRNA-Derived Small RNA Accelerates Tumorigenesis through Crosstalk with Tumor-Associated Macrophages, and Downregulation with Cell Membrane-Modified Polymer Nanoparticles Enables Treatment Response.2025ACS applied materials & interfaces免费全文
  6. Enhancing Chemotherapy Efficacy via an Autologous Erythrocyte-Anchoring Strategy with a Closed-System Drug-Transfer Device.2025ACS biomaterials science & engineering
  7. Gadoxetic Acid-Enhanced MRI-Based Radiomic Models for Preoperative Risk Prediction and Prognostic Assessment of Proliferative Hepatocellular Carcinoma.2025Academic radiology
  8. MRI-Based Models Using Habitat Imaging for Predicting Distinct Vascular Patterns in Hepatocellular Carcinoma.2025Academic radiology
  9. G protein-coupled receptor GPR182 negatively regulates sprouting angiogenesis via modulating CXCL12-CXCR4 axis signaling.2025Angiogenesis免费全文
  10. Evaluation of serum hsa_tsr014055 as a potential biomarker for diagnosis and prognosis of hepatocellular carcinoma.2025Annals of medicine免费全文
  11. Alterations of Krüppel-like Factor Signaling and Potential Targeted Therapy for Hepatocellular Carcinoma.2025Anti-cancer agents in medicinal chemistry
  12. Decoding the role of nucleic acid binding protein 2 in lipid dysregulation and hepatocellular carcinoma progression through LKB1-mediated mitochondrial dysfunction.2025Cellular signalling
  13. tRF-23-R9J89O9N9:A novel liquid biopsy marker for diagnosis of hepatocellular carcinoma.2025Clinica chimica acta; international journal of clinical chemistry
  14. Development and evaluation of a nutritional risk prediction model for patients with hepatocellular carcinoma undergoing transarterial chemoembolisation.2025Clinical and experimental medicine免费全文
  15. Improving Outcomes in Hepatocellular Carcinoma through Integration of Machine Learning: Development of a Tumor-Associated Macrophage Signature.2025Digestive diseases (Basel, Switzerland)
  16. cPDS Promotes Cell Apoptosis by Reducing the Translational Efficiency of BIRC3 mRNA in HCC.2025Digestive diseases and sciences免费全文
  17. Significance of anatomical resection and wide surgical margin for HCC patients with MVI undergoing laparoscopic hepatectomy: A multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  18. ALG3 as a prognostic biomarker and mediator of PD-1 blockade resistance in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  19. Understanding the relationship between cuproptosis and the development of hepatocellular carcinoma: implications for targeted therapies.2025Frontiers in immunology免费全文
  20. Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma.2025Frontiers in immunology免费全文
  21. Exploring the clinical application and biological function of novel tsRNA tsRNA-Asp-5-0002 in hepatocellular carcinoma.2025Gene
  22. KGF secreted from HSCs activates PAK4/BMI1, promotes HCC stemness through PI3K/AKT pathway.2025IUBMB life
  23. Monoterpene Sabinene Suppresses Hepatocarcinoma by Regulating the AKT/mTOR and Bcl-2/Bax Signaling Pathways: An In Vivo and In Vitro Analysis.2025Journal of biochemical and molecular toxicology
  24. tRF-34-P4R8YP9LON4VHM Promotes Hepatocellular Carcinoma Progression and Tumour Cell-Induced Angiogenesis via the MEK/ERK Pathway.2025Journal of cellular and molecular medicine免费全文
  25. Reduction of alternative polarization of macrophages by short-term activated hepatic stellate cell-derived small extracellular vesicles.2025Journal of experimental & clinical cancer research : CR免费全文
  26. NUSAP1 Promotes Immunity and Apoptosis by the SHCBP1/JAK2/STAT3 Phosphorylation Pathway to Induce Dendritic Cell Generation in Hepatocellular Carcinoma.2025Journal of immunotherapy (Hagerstown, Md. : 1997)免费全文
  27. Diagnostic Model for Proliferative HCC Using LI-RADS: Assessing Therapeutic Outcomes in Hepatectomy and TKI-ICI Combination.2025Journal of magnetic resonance imaging : JMRI
  28. Tregs With High CD29 Expression Promote Cell Adhesion and Contribute to the Malignant Transformation of MASLD.2025Liver international : official journal of the International Association for the Study of the Liver免费全文
  29. TMEM115 as an Oncogenic and Immunological Biomarker in Hepatocellular Carcinoma.2025Liver international : official journal of the International Association for the Study of the Liver
  30. Dynamic ubiquitination networks in liver cancer: decoding E3 ligases and deubiquitinases as gatekeepers of therapeutic resistance.2025Medical oncology (Northwood, London, England)
  31. TSPAN15 enhances EMT-mediated metastasis of HCC by promoting autophagy through BTRC-mediated PDCD4 degradation.2025Molecular immunology
  32. COPB2 promotes hepatocellular carcinoma progression through regulation of YAP1 nuclear translocation.2025Oncology research免费全文
  33. Mitochondrial proteins: Potential pathophysiological mechanisms of malignant progression in HCC.2025PloS one免费全文
  34. Constructing a prognostic signature of tumor-associated B lymphocytes in hepatocellular carcinoma via machine learning integration.2025Scientific reports免费全文
  35. mRNA decapping enzyme2 DCP2 expression correlates with progression and prognosis of hepatocellular carcinoma.2025Scientific reports免费全文
  36. Impact of postoperative morbidity on the prognosis of patients with hepatocellular carcinoma after laparoscopic liver resection: a multicenter observational study.2025Scientific reports免费全文
  37. Nodule-in-nodule architecture of hepatocellular carcinomas: enhancement patterns in the hepatobiliary phase and pathological features.2024Abdominal radiology (New York)
  38. Self-Produced O2 CNs-Based Nanocarriers of DNA Hydrophobization Strategy Triggers Photodynamic and Mitochondrial-Derived Ferroptosis for Hepatocellular Carcinoma Combined Treatment.2024Advanced healthcare materials
  39. Comprehensive characterization of Fidgetin on tumor immune microenvironment evaluation and immunotherapy in human hepatocellular carcinoma.2024Aging免费全文
  40. Grading severity of MVI impacts long-term outcomes after laparoscopic liver resection for early-stage hepatocellular carcinoma: A multicenter study.2024American journal of surgery
  41. USP14 exhibits high expression levels in hepatocellular carcinoma and plays a crucial role in promoting the growth of liver cancer cells through the HK2/AKT/P62 axis.2024BMC cancer免费全文
  42. Hsa_circ_0005397 promotes hepatocellular carcinoma progression through EIF4A3.2024BMC cancer免费全文
  43. DNA tetrahedral scaffold-corbelled self-feedback circuit for dual-mode ratiometric biosensing with Ru@COF-LZU1 accelerator.2024Biosensors & bioelectronics
  44. Hsa_circ_0079875 functions as a competitive endogenous RNA to promote hepatocellular carcinoma progression.2024Cell cycle (Georgetown, Tex.)免费全文
  45. Ubiquitin-specific protease 1 facilitates hepatocellular carcinoma progression by modulating mitochondrial fission and metabolic reprogramming via cyclin-dependent kinase 5 stabilization.2024Cell death and differentiation免费全文
  46. Lysosome-Related Genes and RNF19B as Prognostic Markers for Survival and Immunotherapy Efficacy in Hepatocellular Carcinoma.2024Clinical and translational gastroenterology免费全文
  47. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8+ T-cell infiltration in hepatocellular carcinoma.2024Clinical and translational medicine免费全文
  48. Exploration of Key Genes Combining with Immune Infiltration Level andTumor Mutational Burden in Hepatocellular Carcinoma.2024Combinatorial chemistry & high throughput screening
  49. SIAH2-Mediated Degradation of ACSL4 Inhibits the Anti-Tumor Activity of CD8+ T Cells in Hepatocellular Carcinoma.2024Critical reviews in eukaryotic gene expression
  50. Combined RNAi of CTTN and FGF2 Modulates Cell Migration, Invasion and G1/S Transition of Hepatocellular Carcinoma through Ras/ERK Signaling Pathway.2024Current cancer drug targets
  51. Hypoxia-induced TRPM7 promotes glycolytic metabolism and progression in hepatocellular carcinoma.2024European journal of pharmacology
  52. Letter to the editor "A preoperative model for predicting early recurrence in patients undergoing resection for single hepatocellular carcinoma".2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  53. Integrating single cell analysis and machine learning methods reveals stem cell-related gene S100A10 as an important target for prediction of liver cancer diagnosis and immunotherapy.2024Frontiers in immunology免费全文
  54. Targeting liver cancer stem cells: the prognostic significance of MRPL17 in immunotherapy response.2024Frontiers in immunology免费全文
  55. Activated hepatic stellate cell-derived small extracellular vesicles facilitate M2 macrophage polarization and hepatoma progression via miR-27a-3p.2024Frontiers in immunology免费全文
  56. The mechanism of PDE7B inhibiting the development of hepatocellular carcinoma through oxidative stress.2024Frontiers in immunology免费全文
  57. Ubiquitination-specific protease 7 enhances stemness of hepatocellular carcinoma by stabilizing basic transcription factor 3.2024Functional & integrative genomics
  58. Comprehensive Analysis of the Mechanism of Anoikis in Hepatocellular Carcinoma.2024Genetics research免费全文
  59. Is laparoscopic liver resection more suitable for diabetic patients with hepatocellular carcinoma? The debate continues.2024Hepatology international
  60. Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed.2024Hepatology international
  61. Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues.2024Hepatology international
  62. CircGNAO1 suppresses hepatocellular carcinoma progression and metastasis via sponging miR-182-5p and regulating FOXO1 expression.2024International immunopharmacology
  63. Meta-analysis of cryoablation versus radiofrequency ablation in the treatment of malignant liver tumors.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  64. Featured lncRNA-based signature for discriminating prognosis and progression of hepatocellular carcinoma.2024Journal of applied genetics
  65. Body mass index is a risk factor for postoperative morbidity after laparoscopic hepatectomy of hepatocellular carcinoma: a multicenter retrospective study.2024Journal of cancer research and clinical oncology免费全文
  66. Downregulation of GLYAT correlates with tumour progression and poor prognosis in hepatocellular carcinoma.2024Journal of cellular and molecular medicine免费全文
  67. Preoperative Gadoxetic Acid-Enhanced MRI Features for Evaluation of Vessels Encapsulating Tumor Clusters and Microvascular Invasion in Hepatocellular Carcinoma: Creating Nomograms for Risk Assessment.2024Journal of magnetic resonance imaging : JMRI
  68. ACYP2 functions as an innovative nano-therapeutic target to impede the progression of hepatocellular carcinoma by inhibiting the activity of TERT and the KCNN4/ERK pathway.2024Journal of nanobiotechnology免费全文
  69. Lymphocyte Function in Tertiary Lymphoid Structures Predicts Hepatocellular Carcinoma Outcome.2024Laboratory investigation; a journal of technical methods and pathology
  70. Effect of Noise Management in Interventional Radiology Suites on Patients Undergoing Transarterial Chemoembolization: A Retrospective Study.2024Noise & health免费全文
  71. HOMER3 promotes liver hepatocellular carcinoma cancer progression by -upregulating EZH2 and mediating miR-361/GPNMB axis.2024Pathology, research and practice
  72. Upregulation of LHPP by saRNA inhibited hepatocellular cancer cell proliferation and xenograft tumor growth.2024PloS one免费全文
  73. Identification of serum tsRNA-Thr-5-0015 and combined with AFP and PIVKA-II as novel biomarkers for hepatocellular carcinoma.2024Scientific reports免费全文
  74. DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C.2024Scientific reports免费全文
  75. Multi-omics analysis of macrophage-associated receptor and ligand reveals a strong prognostic signature and subtypes in hepatocellular carcinoma.2024Scientific reports免费全文
  76. CircGPC3 promotes hepatocellular carcinoma progression and metastasis by sponging miR-578 and regulating RAB7A/PSME3 expression.2024Scientific reports免费全文
  77. Letter to the Editor on: "Risk factors, patterns, and outcome predictors of late recurrence in patients with hepatocellular carcinoma after curative resection: A large cohort study with long-term follow-up results".2024Surgery
  78. Commentary on "Comparison between laparoscopic liver resection and open liver resection in patients with hepatocellular carcinoma with portal vein tumor thrombosis".2024Surgical endoscopy
  79. Probing Dual Covalent Irreversible Inhibition of EGFR/FGFR4 by Electrophilic-Based Natural Compounds to Overcome Resistance and Enhance Combination Therapeutic Potentials and Management of Hepatocellular Carcinoma (HCC).2024The protein journal
  80. MRPL21 promotes HCC proliferation through TP53 mutation-induced apoptotic resistance.2024Tissue & cell
  81. Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation.2024World journal of gastroenterology免费全文
  82. Computed tomography texture analysis combined with preoperative clinical factors serve as a predictor of early efficacy of transcatheter arterial chemoembolization in hepatocellular carcinoma.2023Abdominal radiology (New York)
  83. Prediction for Aggressiveness and Postoperative Recurrence of Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced Magnetic Resonance Imaging.2023Academic radiology
  84. circSLCO1B7 suppresses the malignant progression of hepatocellular carcinoma via the miR-556-3p/DAB2IP axis.2023Aging免费全文
  85. Expression and function of myelin expression factor 2 in hepatocellular carcinoma.2023BMC gastroenterology免费全文
  86. M7G methylated core genes (METTL1 and WDR4) and associated RNA risk signatures are associated with prognosis and immune escape in HCC.2023BMC medical genomics免费全文
  87. Dehydrocostus Lactone Reduced Malignancy of HepG2 Human Hepatocellular Carcinoma Cells via Down-Regulation of the PI3K/AKT Signaling Pathway.2023Bulletin of experimental biology and medicine
  88. Sestrin2: multifaceted functions, molecular basis, and its implications in liver diseases.2023Cell death & disease免费全文
  89. Identification of anoikis related subtypes and construction of prognostic model in hepatocellular carcinoma.2023Cellular and molecular biology (Noisy-le-Grand, France)
  90. Identification of acetyl-CoA carboxylase alpha as a prognostic and targeted candidate for hepatocellular carcinoma.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  91. KRTCAP2 as an immunological and prognostic biomarker of hepatocellular carcinoma.2023Colloids and surfaces. B, Biointerfaces
  92. RBM12 regulates the progression of hepatocellular cancer via miR-497-5p/CPNE1 Axis.2023Environmental research
  93. Overexpression of TMEM79 combined with SMG5 is related to prognosis, tumor immune infiltration and drug sensitivity in hepatocellular carcinoma.2023European journal of medical research免费全文
  94. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.2023European journal of medical research免费全文
  95. Integrated investigation of the clinical implications and targeted landscape for RNA methylation modifications in hepatocellular carcinoma.2023European journal of medical research免费全文
  96. A commentary on "A new prognostic model predicting hepatocellular carcinoma early recurrence in patients with microvascular invasion who received postoperative adjuvant transcatheter arterial chemoembolization".2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  97. Insights into the Role of Oxidative Stress in Hepatocellular Carcinoma Development.2023Frontiers in bioscience (Landmark edition)
  98. PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  99. Oncogenic Wnt3a is a promising sensitive biomarker for monitoring hepatocarcinogenesis.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  100. Cellular senescence in liver diseases: From mechanisms to therapies.2023International immunopharmacology
  101. Minichromosome maintenance protein family member 6 mediates hepatocellular carcinoma progression by recruiting UBE3A to induce P53 ubiquitination.2023International journal of biological macromolecules
  102. A commentary on 'Significance of anatomical resection and resection margin status in patients with HBV-related hepatocellular carcinoma and microvascular invasion: a multicenter propensity score-matched study'.2023International journal of surgery (London, England)免费全文
  103. Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma.2023Journal of advanced research免费全文
  104. Prognostic related gene index for predicting survival and immunotherapeutic effect of hepatocellular carcinoma.2023Medicine免费全文
  105. Radiomics Based on Contrast-Enhanced CT for Recognizing c-Met-Positive Hepatocellular Carcinoma: a Noninvasive Approach to Predict the Outcome of Sorafenib Resistance.2023Molecular imaging and biology
  106. Tumor-derived exosomes promote macrophages M2 polarization through miR-1-3p and regulate the progression of liver cancer.2023Molecular immunology
  107. RNA-binding motif 4 promotes angiogenesis in HCC by selectively activating VEGF-A expression.2023Pharmacological research
  108. Ginsenoside Rh2: A shining and potential natural product in the treatment of human nonmalignant and malignant diseases in the near future.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  109. Construction of a ceRNA regulatory network to explore potential pathogenesis mechanisms involved in human hepatocellular carcinoma.2023Scientific reports免费全文
  110. DLAT is a promising prognostic marker and therapeutic target for hepatocellular carcinoma: a comprehensive study based on public databases.2023Scientific reports免费全文
  111. A model incorporating histopathology and preoperative gadoxetic acid-enhanced MRI to predict early recurrence of hepatocellular carcinoma without microvascular invasion after curative hepatectomy.2023The British journal of radiology免费全文
  112. Function and biomedical implications of exosomal microRNAs delivered by parenchymal and nonparenchymal cells in hepatocellular carcinoma.2023World journal of gastroenterology免费全文
  113. Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma.2022Aging免费全文
  114. Long-term oncological prognosis after curative-intent liver resection for hepatocellular carcinoma in the young versus the elderly: multicentre propensity score-matching study.2022BJS open免费全文
  115. Nuclear respiratory factor 1 promotes the growth of liver hepatocellular carcinoma cells via E2F1 transcriptional activation.2022BMC gastroenterology免费全文
  116. Using pre-operative radiomics to predict microvascular invasion of hepatocellular carcinoma based on Gd-EOB-DTPA enhanced MRI.2022BMC medical imagingRCT免费全文
  117. Development and Validation of a Novel Circadian Rhythm-Related Signature to Predict the Prognosis of the Patients with Hepatocellular Carcinoma.2022BioMed research international免费全文
  118. Circular RNA hsa_circ_0051040 Promotes Hepatocellular Carcinoma Progression by Sponging miR-569 and Regulating ITGAV Expression.2022Cells免费全文
  119. Screening and Validation of a Carvacrol-Targeting Viability-Regulating Protein, SLC6A3, in Liver Hepatocellular Carcinoma.2022Disease markers免费全文
  120. Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma.2022Frontiers in immunology免费全文
  121. Flap endonuclease 1 Facilitated Hepatocellular Carcinoma Progression by Enhancing USP7/MDM2-mediated P53 Inactivation.2022International journal of biological sciences免费全文
  122. Involvement of microRNAs and their potential diagnostic, therapeutic, and prognostic role in hepatocellular carcinoma.2022Journal of clinical laboratory analysis免费全文
  123. Hsa_circ_0000098 is a novel therapeutic target that promotes hepatocellular carcinoma development and resistance to doxorubicin.2022Journal of experimental & clinical cancer research : CR免费全文
  124. A Web-Based Prediction Model for Estimating the Probability of Post-hepatectomy Major Complications in Patients with Hepatocellular Carcinoma: A Multicenter Study from a Hepatitis B Virus-Endemic Area.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  125. Prognostic Significance of Preoperative Integrated Liver Inflammatory Score in Patients with Hepatocellular Carcinoma.2022Medical science monitor : international medical journal of experimental and clinical research免费全文
  126. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.2022Molecular biology reports
  127. The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook.2022Molecular immunology
  128. Clinicopathological features and genomic profiles of hepatoid adenocarcinoma of the lung: Report of four cases.2022Pathology, research and practice
  129. Associations of MALAT1 and its functional single nucleotide polymorphisms with cancer.2022Pathology, research and practice
  130. Hypoxia-induced RNASEH2A limits activation of cGAS-STING signaling in HCC and predicts poor prognosis.2022Tumori
  131. Elevated serum alpha-fetoprotein levels are associated with poor prognosis of hepatocellular carcinoma after surgical resection: A systematic review and meta-analysis.2021Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  132. RBM23 Drives Hepatocellular Carcinoma by Activating NF-κB Signaling Pathway.2021BioMed research international免费全文
  133. LncRNA DHRS4-AS1 ameliorates hepatocellular carcinoma by suppressing proliferation and promoting apoptosis via miR-522-3p/SOCS5 axis.2021Bioengineered免费全文
  134. Long non-coding RNA SNHG22 facilitates hepatocellular carcinoma tumorigenesis and angiogenesis via DNA methylation of microRNA miR-16-5p.2021Bioengineered免费全文
  135. LINC00839/miR-144-3p/WTAP (WT1 Associated protein) axis is involved in regulating hepatocellular carcinoma progression.2021Bioengineered免费全文
  136. H2A.Z acetylation by lincZNF337-AS1 via KAT5 implicated in the transcriptional misregulation in cancer signaling pathway in hepatocellular carcinoma.2021Cell death & disease免费全文
  137. The Emerging Roles of Exosomes in the Chemoresistance of Hepatocellular Carcinoma.2021Current medicinal chemistry
  138. The role of ceRNA-mediated diagnosis and therapy in hepatocellular carcinoma.2021Hereditas免费全文
  139. CLTRN, Regulated by NRF1/RAN/DLD Protein Complex, Enhances Radiation Sensitivity of Hepatocellular Carcinoma Cells Through Ferroptosis Pathway.2021International journal of radiation oncology, biology, physics
  140. Predictive value of and relationship between the gamma-glutamyl transpeptidase to lymphocyte ratio and CT features in hepatocellular carcinoma patients with postoperative adjuvant TACE.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  141. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.2021Journal of cancer research and therapeutics
  142. DNMT1-induced miR-378a-3p silencing promotes angiogenesis via the NF-κB signaling pathway by targeting TRAF1 in hepatocellular carcinoma.2021Journal of experimental & clinical cancer research : CR免费全文
  143. A Derivative of Piperlongumine and Ligustrazine as a Potential Thioredoxin Reductase Inhibitor in Drug-Resistant Hepatocellular Carcinoma.2021Journal of natural products
  144. MicroRNA-92b-3p promotes the progression of liver fibrosis by targeting CREB3L2 through the JAK/STAT signaling pathway.2021Pathology, research and practice
  145. Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth.2021World journal of gastroenterology免费全文
中文论文(未计入)6
  1. [CENPI promotes the migration of liver cancer cells and the epithelial-mesenchymal transition process by activating the RAS/MEK/ERK signaling axis].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Hepatobiliary phase image manifestation classification and pathological features of nodules in nodules accompanied by hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  3. [Overexpression of tuftelin and KLF-5 and its clinicopathological features in hepatitis B virus-related hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  4. [Alteration of Wnt3a overexpression and its early monitoring value during hepatocellular carcinogenesis].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  5. [Value of abnormal expression of Krüppel-like zinc-finger protein transcription factor 5 in the diagnosis and prognosis of liver cancer].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  6. [Expression of tuftelin protein and its clinical value in HBV-related liver cancer tissues].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  2. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects已终止NCT03236649研究中心III期2017-09 启动
  3. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects状态不明NCT03236636研究中心III期2017-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 107 篇,占 1.1%。

牵头论文
107
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 161620212022: 161620222023: 171720232024: 202020242025: 34342025

南通有 1 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 邀请入组
    Screening of Small Non-coding RNAs as an Auxiliary Diagnostic Biomarker for Gastric Cancer
    分期
    未注明
    开始
    2023-12
    登记号
    NCT06776835

    年龄 18 岁 至 85 岁(登记的条件)

    牵头:南通大学附属医院南通

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期手术早期发现与内镜
论文中的科室病理/检验科普外/肝胆胰外科肿瘤内科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文107
  1. Overexpression of miR-195-5p Suppresses Gastric Cancer Progression by Regulating LAMP2-Mediated Autophagy.2026Biochemical genetics免费全文
  2. [Expression of Concern] Effects of cullin 4B on the proliferation and invasion of human gastric cancer cells.2026Molecular medicine reports免费全文
  3. Telomere-protecting protein 1 promotes gastric cancer cell metastasis via enhancing endoplasmic reticulum stress.2026The Journal of biological chemistry免费全文
  4. Tumor microenvironment-driven ST6Gal-Ⅰ activation promotes aggressiveness in gastric signet-ring cell carcinoma via ITGβ1/FAK/Paxillin signaling.2026Tissue & cell
  5. VSIG2 hinders gastric cancer progression by suppressing ANXA2-mediated NF-κB pathway activation.2025Acta biochimica et biophysica Sinica免费全文
  6. Development and validation of a diagnostic and screening method for gastric cancer by combining new gastric cancer screening score and serum biomarkers: a prospective study.2025BMC cancer免费全文
  7. Granzyme B Promotes Proliferation, Migration and EMT Process in Gastric Cancer.2025Biochemical genetics
  8. Enhanced IL36RN Expression and Its Association With Immune Microenvironment Predicts Poor Prognosis in Gastric Cancer.2025Cancer medicine免费全文
  9. The MIR181A2HG/miR-5680/VCAN-CD44 Axis Regulates Gastric Cancer Lymph Node Metastasis by Promoting M2 Macrophage Polarization.2025Cancer medicine免费全文
  10. A novel serum biomarker Enhancer RNA RASSF8-AS1 promotes the progression of gastric cancer.2025Carcinogenesis
  11. Systematic assessment of serum i-tRF-AsnGTT in gastric cancer: a potential clinical biomarker.2025Carcinogenesis
  12. NLRP12 decreases TRIM25-mediated HK2 degradation to promote glycolysis and H3K18la in gastric cancer.2025Cell death & disease免费全文
  13. The cancer-testis lncRNA LINC01940 promotes gastric cancer malignant progression and chemoresistance by enhancing ribosome biogenesis via TAF15-mediated NOL11 SUMOylation.2025Cellular & molecular biology letters免费全文
  14. SPTSSA facilitates gastric cancer progression with modulating PD-L1 in immunomicroenvironment through Wnt/β-catenin pathway.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  15. PRDX2 promotes gastric cancer progression by forming a feedback loop with PKM2/STAT3 axis.2025Cellular signalling
  16. Serum tRF-18-HR05X6D2 may serve as a promising potential diagnostic biomarker for gastric cancer.2025Clinical and experimental medicine免费全文
  17. Serum STARD4-AS1 as a Novel Marker for Gastric Cancer Diagnosis and Promotes Gastric Cancer Progression.2025Clinical and translational gastroenterology免费全文
  18. Exploring the diagnostic potential of serum 5'tRF-Lys as a novel gastric cancer biomarker.2025Clinical biochemistry
  19. Development and validation of a preoperative CT-based risk score integrating morphological and body composition parameters to predict recurrence-free survival in gastric cancer patients following curative surgery.2025European journal of radiology
  20. Baseline and early changes in CT body composition can predict recurrence-free survival after radical gastrectomy: A sex-specific study.2025European journal of radiology
  21. Cost-effectiveness analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced gastric cancer.2025Frontiers in public health免费全文
  22. Elucidating the Role of THPO and Related Molecular Markers in Lymph Node Metastasis and Prognosis of Gastric Cancer: Insights From TCGA Data Analysis.2025Genetics research免费全文
  23. The role of CD101 and Tim3 in the immune microenvironment of gastric cancer and their potential as prognostic biomarkers.2025International immunopharmacology
  24. Prp19/CDC5L promotes gastric cancer via activation of the MAPK pathway-mediated homologous recombination.2025International journal of biological sciences免费全文
  25. CSF2RA promotes gastric cancer progression through activation of the JAK2/STAT3 signaling pathway.2025Journal of molecular histology
  26. miR-378d suppresses gastric cancer metastasis by targeting METTL4 to inhibit epithelial-mesenchymal transition.2025Journal of molecular histology
  27. MFAP2 promotes the malignant progression of gastric cancer via activating the PI3K/AKT signaling pathway.2025Journal of receptor and signal transduction research
  28. HECW1-Mediated Ubiquitination of HIPK2 Drives Metastasis in Gastric Cancer Through the AKT Signaling Pathway.2025Laboratory investigation; a journal of technical methods and pathology
  29. Endoscopic diagnosis of gastric carcinoma of fundic gland type: A case report.2025Medicine免费全文
  30. NLRP3 inflammasome expression affects immune cell infiltration and clinical prognosis in Helicobacter pylori infection‑associated gastric cancer.2025Molecular medicine reports免费全文
  31. Nociceptive neurons promote gastric tumour progression via a CGRP-RAMP1 axis.2025Nature免费全文
  32. Identification and potential mechanism of a novel gastric cancer suppressor tRF-24-6VR8K09LE9.2025Naunyn-Schmiedeberg's archives of pharmacology
  33. lncRNA SNHG4 enhanced gastric cancer progression by modulating miR-409-3p/CREB1 axis.2025Oncology research免费全文
  34. NKAIN1 expression relates to the immune evasion and prognosis of gastric cancer.2025Scientific reports免费全文
  35. MAGEA11 promotes GC proliferation, migration, and invasion through activation of E2F1 transcriptional activity.2025Scientific reports免费全文
  36. Prognostic molecular subtype reveals the heterogeneity of tumor immune microenvironment in gastric cancer.2025Scientific reports免费全文
  37. Mechanism and role of H. pylori CagA-induced NLRP3 inflammasome in gastric cancer immune cell infiltration.2025Scientific reports免费全文
  38. Mapping the landscape of ovarian metastases of gastric cancer: insights, trends, and emerging perspectives.2025World journal of surgical oncology免费全文
  39. Machine learning for identifying tumor stemness genes and developing prognostic model in gastric cancer.2024Aging免费全文
  40. Survival impact of gastrectomy and chemotherapy on gastric signet ring-cell carcinoma with different metastatic lesions: A population-based study.2024Asian journal of surgery
  41. Potential clinical significance of ALDH3B1 in auxiliary diagnosis of gastric cancer.2024Biomarkers in medicine
  42. Diagnostic and prognostic value of the gasdermins in gastric cancer.2024Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas免费全文
  43. Human circular RNA hsa_circ_0000231 clinical diagnostic effectiveness as a new tumor marker in gastric cancer.2024Cancer reports (Hoboken, N.J.)免费全文
  44. Circular RNA circWNK1 inhibits the progression of gastric cancer via regulating the miR-21-3p/SMAD7 axis.2024Cancer science
  45. RUNX1, FUS, and ELAVL1-induced circPTPN22 promote gastric cancer cell proliferation, migration, and invasion through miR-6788-5p/PAK1 axis-mediated autophagy.2024Cellular & molecular biology letters免费全文
  46. Clinical value assessment for serum hsa_tsr013526 in the diagnosis of gastric carcinoma.2024Environmental toxicology
  47. Dysregulated transfer RNA-derived small RNAs as potential gastric cancer biomarkers.2024Experimental biology and medicine (Maywood, N.J.)免费全文
  48. PCDHGA10 as a potential prognostic biomarker and correlated with immune infiltration in gastric cancer.2024Frontiers in immunology免费全文
  49. Identification of an autophagy- and macropinocytosis-related prognostic signature for the prediction of prognosis and therapeutic response in gastric cancer.2024Genes & genomics
  50. SCYL1-mediated regulation of the mTORC1 signaling pathway inhibits autophagy and promotes gastric cancer metastasis.2024Journal of cancer research and clinical oncology免费全文
  51. A novel tRNA-derived fragment tRF-17-18VBY9M works as a potential diagnostic biomarker for gastric cancer.2024Journal of cancer research and clinical oncology免费全文
  52. Highly expressed B3GALT5-AS1 contributes to gastric cancer progression by recruiting WDR5 to mediate B3GALT5 and regulating β-catenin/ZEB1 axis.2024Journal of cellular and molecular medicine免费全文
  53. Clinical Effect of Tumor-Specific Total Nutrients in Patients with Adjuvant Chemotherapy After Radical Gastric Cancer Resection: A Randomized Controlled Trial.2024Journal of gastrointestinal cancerRCT免费全文
  54. Implementation of the Robocare nursing model for patients undergoing da Vinci robot-assisted radical gastrectomy for gastric cancer.2024Journal of robotic surgery
  55. ECHDC2 inhibits the proliferation of gastric cancer cells by binding with NEDD4 to degrade MCCC2 and reduce aerobic glycolysis.2024Molecular medicine (Cambridge, Mass.)免费全文
  56. High expression of TRIP13 is associated with tumor progression in H. pylori infection induced gastric cancer.2024Mutation research
  57. Long non-coding RNA AC010457.1 promotes the growth and EMT of gastric cancer via the PI3K/AKT axis.2024Pathology, research and practice
  58. CircBIRC6 facilitates the malignant progression via miR-488/GRIN2D-mediated CAV1-autophagy signal axis in gastric cancer.2024Pharmacological research
  59. Clinical features of upper gastrointestinal endoscopy in 3146 patients: a 9-year retrospective cohort study in Zanzibar Archipelago, Tanzania.2023African health sciences免费全文
  60. Immunobiological signatures and the emerging role of SPP1 in predicting tumor heterogeneity, malignancy, and clinical outcomes in stomach adenocarcinoma.2023Aging免费全文
  61. The landscape of enhancer RNA identify prognosis-related molecular subtypes in gastric cancer.2023Cancer medicine免费全文
  62. Ubiquitin-specific peptidase 24 accelerates aerobic glycolysis and tumor progression in gastric carcinoma through stabilizing PLK1 to activate NOTCH1.2023Cancer science免费全文
  63. MicroRNA miR-1275 coordinately regulates AEA/LPA signals via targeting FAAH in lipid metabolism reprogramming of gastric cancer.2023Cell death & disease免费全文
  64. Overexpression of ferroptosis-related genes FSP1 and CISD1 is related to prognosis and tumor immune infiltration in gastric cancer.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  65. Exosomal circ_0091741 promotes gastric cancer cell autophagy and chemoresistance via the miR-330-3p/TRIM14/Dvl2/Wnt/β-catenin axis.2023Human cell
  66. Hsa_circ_0001479 accelerates tumorigenesis of gastric cancer and mediates immune escape.2023International immunopharmacology
  67. Serum tRF-27-FDXXE6XRK45 as a Promising Biomarker for the Clinical Diagnosis in Gastric Cancer.2023International journal of medical sciences免费全文
  68. Serum circular RNA hsa_circ_0000702 as a novel biomarker for diagnosis of gastric cancer.2023Journal of clinical laboratory analysis免费全文
  69. CHSY3 promotes proliferation and migration in gastric cancer and is associated with immune infiltration.2023Journal of translational medicine免费全文
  70. A comprehensive evaluation of serum tRF-29-R9J8909NF5JP as a novel diagnostic and prognostic biomarker for gastric cancer.2023Molecular carcinogenesis
  71. SLC7A11 promotes the progression of gastric cancer and regulates ferroptosis through PI3K/AKT pathway.2023Pathology, research and practice
  72. Gastric ectopic pancreas adenocarcinoma: A case report and literature review.2023Saudi medical journal免费全文
  73. Bacterial lipopolysaccharide related genes signature as potential biomarker for prognosis and immune treatment in gastric cancer.2023Scientific reports免费全文
  74. High expression of GPR176 predicts poor prognosis of gastric cancer patients and promotes the proliferation, migration, and invasion of gastric cancer cells.2023Scientific reports免费全文
  75. Dishevelled segment polarity protein 2 promotes gastric cancer progression through Wnt/β-catenin pathway.2023Tissue & cell
  76. Effect of bilateral paravertebral nerve block on cognitive function in elderly patients undergoing radical gastrectomy for gastric cancer: a prospective randomized double-blind controlled trial.2022BMC anesthesiologyRCT免费全文
  77. HDAC4 promotes the growth and metastasis of gastric cancer via autophagic degradation of MEKK3.2022British journal of cancer免费全文
  78. NDUFS4 promotes tumor progression and predicts prognosis in gastric cancer.2022Carcinogenesis
  79. Kinase DYRK2 acts as a regulator of autophagy and an indicator of favorable prognosis in gastric carcinoma.2022Colloids and surfaces. B, Biointerfaces
  80. Outcomes of laparoscopic versus open total gastrectomy with D2 lymphadenectomy for gastric cancer: a systematic review and meta-analysis.2022European journal of medical research免费全文
  81. Inhibition of Musashi-1 enhances chemotherapeutic sensitivity in gastric cancer patient-derived xenografts.2022Experimental biology and medicine (Maywood, N.J.)免费全文
  82. A Multi-Omics Study on the Effect of Helicobacter Pylori-Related Genes in the Tumor Immunity on Stomach Adenocarcinoma.2022Frontiers in cellular and infection microbiology免费全文
  83. Identifying immune cells-related phenotype to predict immunotherapy and clinical outcome in gastric cancer.2022Frontiers in immunology免费全文
  84. RUNX3-mediated circDYRK1A inhibits glutamine metabolism in gastric cancer by up-regulating microRNA-889-3p-dependent FBXO4.2022Journal of translational medicine免费全文
  85. Diagnostic Value of Circular RNA hsa_circ_0002874 Expression in Peripheral Blood of Patients with Gastric Cancer.2022Laboratory medicine
  86. Evaluation of serum tRF-23-Q99P9P9NDD as a potential biomarker for the clinical diagnosis of gastric cancer.2022Molecular medicine (Cambridge, Mass.)免费全文
  87. Immune-related gene TM4SF18 could promote the metastasis of gastric cancer cells and predict the prognosis of gastric cancer patients.2022Molecular oncology免费全文
  88. Hsa_circ_0000437 promotes pathogenesis of gastric cancer and lymph node metastasis.2022Oncogene
  89. Block of Proliferation 1 Promotes Proliferation, Invasion and Epithelial Mesenchymal Transformation in Gastric Cancer.2022Oxidative medicine and cellular longevity免费全文
  90. Relationship between histological mixed-type early gastric cancer and lymph node metastasis: A systematic review and meta-analysis.2022PloS one免费全文
  91. PRSS2 overexpression relates to poor prognosis and promotes proliferation, migration and invasion in gastric cancer.2022Tissue & cell
  92. ERCC6L promotes cell growth and metastasis in gastric cancer through activating NF-κB signaling.2021Aging免费全文
  93. Transcription factor PAX4 facilitates gastric cancer progression through interacting with miR-27b-3p/Grb2 axis.2021Aging免费全文
  94. MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling.2021Aging免费全文
  95. Clinicopathological features and lymph node metastasis risk in early gastric cancer with WHO criteria in China: 304 cases analysis.2021Annals of diagnostic pathology
  96. The correlation of microRNA-499 rs3746444 T>C locus with the susceptibility of gastric cancer: from a case-control study to a meta-analysis.2021Bioscience reports免费全文
  97. GARP Correlates With Tumor-Infiltrating T-Cells and Predicts the Outcome of Gastric Cancer.2021Frontiers in immunology免费全文
  98. Circulating serum exosomal miR-92a-3p as a novel biomarker for early diagnosis of gastric cancer.2021Future oncology (London, England)
  99. A commentary on "Updated evaluation of endoscopic submucosal dissection versus surgery for early gastric cancer: A systematic review and meta-analysis" [Int. J. Surg. 73 (2020) 28-41].2021International journal of surgery (London, England)
  100. GHR is involved in gastric cell growth and apoptosis via PI3K/AKT signalling.2021Journal of cellular and molecular medicine免费全文
  101. A systematic review of primary gastric diffuse large B-cell lymphoma: Clinical diagnosis, staging, treatment and prognostic factors.2021Leukemia research
  102. Diagnostic value of exosome derived long noncoding RNA in gastric cancer in Chinese population: A PRISMA-compliant systematic review and meta-analysis.2021Medicine免费全文
  103. SLC6A3 as a potential circulating biomarker for gastric cancer detection and progression monitoring.2021Pathology, research and practice
  104. MiR-216b regulates the tumorigenesis of gastric cancer by targeting PXN.2021Pathology, research and practice
  105. The effects of video based nursing education on perioperative anxiety and depression in patients with gastric cancer.2021Psychology, health & medicineRCT
  106. The Association Between Heavy Alcohol Use and Gastric Cancer.2021The American journal of gastroenterology
  107. Assessment of the value of adjuvant radiotherapy for treatment of gastric adenocarcinoma based on pattern of post-surgical progression.2021World journal of surgical oncology免费全文
中文论文(未计入)7
  1. [Epidemiological characteristics of cancer mortality in the elderly in Qidong, 1972-2021].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. Transfer RNA-derived fragment tRF-23-Q99P9P9NDD promotes progression of gastric cancer by targeting ACADSB.2024Journal of Zhejiang University. Science. B免费全文
  3. [Tubular adenocarcinoma and signet ring cell carcinoma arising in gastric inverted hyperplastic polyp: report of a case].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Hsa_circ_0000670 promoted the progression of gastric cancer through the miR-515-5p/SIX1 molecular axis].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  5. [Long-term trend of gastric cancer survival rate in Qidong, 1972-2016].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  6. [Epidemic characteristics of stomach cancer mortality in Qidong during 1972-2016].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  7. [Expression of PTTG1 in gastric adenocarcinoma tissues and its relationship with prognosis].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Screening of Small Non-coding RNAs as an Auxiliary Diagnostic Biomarker for Gastric Cancer邀请入组NCT06776835牵头方2023-12 启动
  2. Laparoscopic Gastric Function Preserving Surgery Combined With Resection of the Anterior Lymphatic Drainage Area状态不明NCT05160753牵头方不分期2022-01 启动
  3. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer已完成NCT01774786研究中心III期2013-06 启动
  4. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动
  5. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer已终止NCT01641939研究中心II/III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 9 篇,占 0.4%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 3320242025: 442025

南通有 3 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室放疗科

这些论文过半是实验室或动物研究。

牵头的论文9
  1. CoFe2O4-Based Multifunctional Nanozymes Remodel Tumor Redox Balance for Enhanced Osteosarcoma Treatment.2025International journal of nanomedicine
  2. Hybrid membranes-mediated biomimetic-nanoparticle carrying miR-665 for effective tumor treatment by remodeling tumor microenvironment.2025International journal of pharmaceutics
  3. PiRNA hsa_pir_018849 promotes the proliferation and invasion of osteosarcoma cells by regulating the stability of CCN5 mRNA.2025Journal of orthopaedic surgery and research
  4. The zinc finger protein560(ZNF560) functions as a novel oncogenic gene in osteosarcoma.2025Scientific reports
  5. Silencing FUT4 Inhibits the Progression of Osteosarcoma through Activation of FOXO1.2024Current pharmaceutical design
  6. TET3 Protein Represses Proliferation of the MG-63 Human Osteosarcoma Cell Line by Regulating DNA Demethylation: an Epigenetic Study.2024Folia biologica
  7. PDE1B, a potential biomarker associated with tumor microenvironment and clinical prognostic significance in osteosarcoma.2024Scientific reports
  8. Circular RNA circFOXP1 promotes angiogenesis by regulating microRNA -127-5p/CDKN2AIP signaling pathway in osteosarcoma.2021Bioengineered
  9. A natural product phillygenin suppresses osteosarcoma growth and metastasis by regulating the SHP-1/JAK2/STAT3 signaling.2021Bioscience, biotechnology, and biochemistry
早期论文(2016–2020 年)7
  1. PENK inhibits osteosarcoma cell migration by activating the PI3K/Akt signaling pathway.2020Journal of orthopaedic surgery and research
  2. MicroRNA-222 contributed to cell proliferation, invasion and migration via regulating YWHAG in osteosarcoma.2018European review for medical and pharmacological sciences
  3. miR-27a-3p promotes the malignant phenotypes of osteosarcoma by targeting ten-eleven translocation 1.2018International journal of oncology
  4. Downregulation of 14-3-3β inhibits proliferation and migration in osteosarcoma cells.2018Molecular medicine reports
  5. Downregulation of NKD1 in human osteosarcoma and its clinical significance.2018Molecular medicine reports
  6. Upregulation of HOXB7 promotes proliferation and metastasis of osteosarcoma cells.2017Molecular medicine reports
  7. CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma.2016International immunopharmacology

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025

南通有 1 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.9%。

牵头论文
10
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 4420232024: 3320242025: 222025

南通有 1 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文10
  1. ALDOC promotes neuroblastoma progression and modulates sensitivity to chemotherapy drugs by enhancing aerobic glycolysis.2025Frontiers in immunology
  2. Correlation of senescence-related gene FEN1 on neuroblastoma progression and cisplatin chemotherapy sensitivity.2025Oncology research
  3. LINC00894 inhibited neuron cellular apoptosis and regulated activating transcription factor 3 expression.2024Gene
  4. Radioprotective effect of Ginkgolide B on brain: the mediating role of DCC/MST1 signaling.2024International journal of radiation biology
  5. Homocysteine-potentiated Kelch-like ECH-associated protein 1 promotes senescence of neuroblastoma 2a cells via inhibiting ubiquitination of β-catenin.2024The European journal of neuroscience
  6. miR-6076 targets BCL6 in SH-SY5Y cells to regulate amyloid-β-induced neuronal damage.2023Journal of cellular and molecular medicine
  7. HIV-1 subtype B Tat enhances NOTCH3 signaling in astrocytes to mediate oxidative stress, inflammatory response, and neuronal apoptosis.2023Journal of neurovirology
  8. Disruption of the ADAM17/NF-κB feedback loop in astrocytes ameliorates HIV-1 Tat-induced inflammatory response and neuronal death.2023Journal of neurovirology
  9. TRAF4 Silencing Induces Cell Apoptosis and Improves Retinoic Acid Sensitivity in Human Neuroblastoma.2023Neurochemical research
  10. Dexmedetomidine inhibits cerebral nerve cell apoptosis after cerebral hemorrhage in rats via the Nrf2/HO-1/NQO1 signaling pathway.2022European review for medical and pharmacological sciences
早期论文(2016–2020 年)5
  1. MicroRNA-138 promotes neuroblastoma SH-SY5Y cell apoptosis by directly targeting DEK in Alzheimer's disease cell model.2020BMC neuroscience
  2. Protective Effect of Fucoidan against MPP+-Induced SH-SY5Y Cells Apoptosis by Affecting the PI3K/Akt Pathway.2020Marine drugs
  3. NLRP3 Inflammasome Activation Leads to Epileptic Neuronal Apoptosis.2018Current neurovascular research
  4. Silencing the ACAT1 Gene in Human SH-SY5Y Neuroblastoma Cells Inhibits the Expression of Cyclo-Oxygenase 2 (COX2) and Reduces β-Amyloid-Induced Toxicity Due to Activation of Protein Kinase C (PKC) and ERK.2018Medical science monitor : international medical journal of experimental and clinical research
  5. Down-regulation of C-terminal binding protein 2 (CtBP2) inhibits proliferation, migration, and invasion of human SHSY5Y cells in vitro.2017Neuroscience letters
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Identification of New Gene Spliceosomes in Neuroblastoma状态不明NCT06502210牵头方2024-04 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 16 篇,占 0.9%。

牵头论文
16
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 4420222023: 3320232024: 1120242025: 552025

南通有 1 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
    分期
    I/II期
    开始
    2023-11
    登记号
    NCT06246162

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:南通大学附属医院南通

  2. 正在招募
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    分期
    未注明
    开始
    2026-06
    登记号
    NCT07663253

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属中山医院;另有 9 家列出的医院为研究中心上海、北京、南宁、南通、广州、成都、昆明、武汉、西安、郑州

  3. 正在招募
    A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
    分期
    未注明
    开始
    2024-05
    登记号
    NCT06497738

    年龄 65 岁 至 未注明(登记的条件)

    牵头:江苏省人民医院(南医大一附院);另有 2 家列出的医院为研究中心南京、南通、常州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层联合用药复发与耐药
论文中的科室病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文16
  1. The Causal Relationship between Lipid Metabolites and Multiple Myeloma Risk: A Mendelian Randomization Study.2026Acta haematologica
  2. Effect of Bortezomib Treatment in Multiple Myeloma on Blood Coagulation Function, Renal Function, Immune Function, and the NF-κB Pathway-Associated Indicators.2025British journal of hospital medicine (London, England : 2005)
  3. Extracellular vesicle-mediated delivery of circp53 suppresses the progression of multiple cancers by activating the CypD/TRAP/HSP90 pathway.2025Experimental & molecular medicine免费全文
  4. NAT10 contributes to the progression of multiple myeloma through ac4C modification of GPR37.2025Hematology (Amsterdam, Netherlands)
  5. Downregulated expression of dual-specificity phosphatase-1 in multiple myeloma as a predictor of poor survival outcomes.2025Hematology (Amsterdam, Netherlands)
  6. Single-cell and bulk transcriptomics uncovers PRKD2-driven tumor stemness and progression in multiple myeloma.2025Scientific reports免费全文
  7. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling.2024Expert opinion on drug safety
  8. Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience.2023Annals of hematology
  9. RING box protein-1(RBX1), a key component of SCF E3 ligase, induced multiple myeloma cell drug-resistance though suppressing p27.2023Cancer biology & therapy免费全文
  10. YY1-induced LncRNA-TUG1 elevates YOD1 to promote cell proliferation and inhibit bortezomib sensitivity in multiple myeloma.2023Leukemia & lymphoma
  11. Significance of a tumor microenvironment-mediated P65-miR-30a-5p-BCL2L11 amplification loop in multiple myeloma.2022Experimental cell research
  12. The role of cystatin C in multiple myeloma.2022International journal of laboratory hematology
  13. Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab.2022Technology in cancer research & treatment免费全文
  14. The Prognostic Role of Cyclin D1 in Multiple Myeloma: A Systematic Review and Meta-Analysis.2022Technology in cancer research & treatment免费全文
  15. Serum hsa_circ_0087776 as a new oncologic marker for the joint diagnosis of multiple myeloma.2021Bioengineered免费全文
  16. Decellularized ECM derived from normal bone involved in the viability and chemo-sensitivity in multiple myeloma cells.2021Experimental cell research
中文论文(未计入)1
  1. [Expression and Clinical Significance of LINC00475 in Multiple Myeloma].2024Zhongguo shi yan xue ye xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma正在招募NCT06246162牵头方I/II期2023-11 启动
  2. The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients状态不明NCT05802992牵头方III期2022-03 启动
  3. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients正在招募NCT07663253研究中心2026-06 启动
  4. A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma正在招募NCT06497738研究中心2024-05 启动
  5. SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease已完成NCT05900882研究中心II期2022-07 启动
  6. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  7. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  8. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

南通有 1 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题促血小板生成药物免疫抑制治疗

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.8%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

南通有 1 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题淋巴瘤及肿瘤相关噬血诊断与预后治疗方案
论文中的科室肿瘤内科
牵头的论文3
  1. The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients.2024Annals of hematology
  2. Clinicopathological characteristics, prognostic factors, and outcomes of elderly patients with lymphoma-associated hemophagocytic lymphohistiocytosis: A multicenter analysis.2024Cancer medicine免费全文
  3. The Dosage Recommendation of Cyclosporin in Children with Hemophagocytic Lymphohistiocytosis based on Population Pharmacokinetic Model.2023Current pharmaceutical design
PubMed 以外找到的论文(未计入)6
  1. Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis2024Blood会议摘要
  2. Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients2024Blood会议摘要
  3. Clinical Significance of Serum High-Density Lipoprotein Cholesterol and Its Dynamic Change in Patients with Lymphoma-Associated Hemophagocytic Lymphohistiocytosis2023Blood会议摘要
  4. High Prevalence of MYD88 and CD79B Mutations and PD-L1 Alterations in Bone Marrow Large B Cell Lymphoma Associated with Hemophagocytic Lymphohistiocytosis2023Blood会议摘要
  5. Histiocytic Necrotizing Lymphadenitis with Hemophagocytic Lymphohistiocytosis: A Single-Center Analysis of Five Cases2023Blood会议摘要
  6. The Clinical Significance and Prognostic Value of Serum Beta-2 Microglobulin in Adult Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 326 Patients2023Blood会议摘要

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年没有牵头血友病 A的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南通有 1 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.进行中,不再招募NCT07684898研究中心III期2026-06 启动
  2. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment进行中,不再招募NCT07663903研究中心III期2026-04 启动
  3. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein已完成NCT06142552研究中心III期2023-12 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

南通有 1 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

南通有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 0020242025: 222025

南通有 1 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.6%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025

南通有 1 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

南通有 1 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

南通有 1 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    分期
    III期
    开始
    2025-07
    登记号
    NCT06963827

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文1
  1. Identification of key necroptosis-related genes and immune landscape in patients with immunoglobulin A nephropathy.2024BMC nephrology
早期论文(2016–2020 年)1
  1. BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6/NF‑κB signaling pathway in glomerular mesangial cells.2020Molecular medicine reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy正在招募NCT06963827研究中心III期2025-07 启动
  2. Atrasentan in Patients With IgA Nephropathy进行中,不再招募NCT04573478研究中心III期2020-12 启动
  3. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

南通有 1 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年没有牵头先天性巨结肠的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南通有 1 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. A homozygous MITF mutation leads to familial Waardenburg syndrome type 4.2019American journal of medical genetics. Part A

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.8%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

南通有 1 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

南通有 1 家医院列在Leber 遗传性视神经病变下全国有 32 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

南通大学附属医院

Affiliated Hospital of Nantong University

南通

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Nantong University; Affiliated Tumor Hospital of Nantong University; Second Affiliated Hospital of Nantong University; Nantong University Affiliated Hospital; Medical College of Nantong University; Affiliated Cancer Hospital of Nantong University; Taizhou People's Hospital Affiliated to Nantong University; Tumor Hospital Affiliated to Nantong University

提出更正下载数据